Back to search results

Liver Cancer

A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (REACH-2)

JVDE | {{ defaultRegistry.registryAnchorText }} NCT02435433 {{ currentLocaleObject.registryAnchorText }}

Study Purpose

The purpose of this study is to evaluate the safety and efficacy of ramucirumab in participants with hepatocellular carcinoma (HCC) (liver cancer) and elevated baseline alpha-fetoprotein.

Time Commitment

Your participation in this trial could last up to 3-5 months depending on on how you and your tumor respond

Key Participation Requirements Tool Tip Icon

All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria


Male Female


18+ years
  • Participant must have a confirmed diagnosis of liver cancer or a diagnosis of cirrhosis and a tumor with imaging characteristics of liver cancer

  • Participants in the United States, European Union, Taiwan and Hong Kong must have previously taken a therapy other than sorafenib for the treatment of liver cancer

  • Participants in China must have previously taken sorafenib for the treatment of liver cancer

  • Participant must be willing to provide blood for research

  • Female participant must not be pregnant or breastfeeding and must also use highly effective contraceptive method during study participation, if not surgically sterile or postmenopausal

  • Male participant must be surgically sterile or compliant with a highly effective contraceptive method

  • Participant must not have undergone a prior liver transplant

  • Participant must not have uncontrolled hypertension, HIV, AIDS, active or uncontrolled clinically serious infection, ongoing or recent drug abuse, uncontrolled thrombotic or bleeding disorder or a bowel obstruction

Where to Participate

Where to Participate

Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location Status
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
{{site.siteStatus | translate}}
Closest Location to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
{{site.siteStatus | translate}}
Other Location(s) to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
{{site.siteStatus | translate}}

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.